Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + cytokine-induced killer cells
- Development stage
- Unknown
- Lead developer
- Changzhou First People's Hospital
- Modality
- Cell Therapies, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of the small molecule tyrosine kinase inhibitor apatinib and autologous cytokine-induced killer (CIK) cells. Apatinib is a potent and highly selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), which blocks the signaling pathways necessary for tumor angiogenesis. CIK cells are a heterogeneous population of ex vivo expanded T lymphocytes, characterized by the co-expression of CD3 and CD56, generated from peripheral blood mononuclear cells in the presence of cytokines like interferon-gamma and interleukin-2. These cells possess potent, non-major histocompatibility complex (MHC)-restricted cytotoxic activity against various tumor types. The combination is being investigated by The First People's Hospital of Changzhou as a third-line treatment for patients with advanced lung adenocarcinoma who have wild-type EGFR.
- Other names
- Apatinib plus CIKApatinib + CIK cells
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on apatinib + cytokine-induced killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + cytokine-induced killer cells.